ANILERIDINE

US Previously Marketed

First approved in 1957

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N2O2
Molecular Weight	352.4699
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=LKYQLAWMNBFNJT-UHFFFAOYSA-N

InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278

Aniledrine is a narcotic pain reliver. The drug was prescribed as an analgesic in anaesthesia (Leritine brand name), however, it is no longer available on the market. Although the exact mechanism is not fully understood, aniledrine appears to elicit its action by binding to endorphine receptors in CNS.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278	Curative		Approved 8429	LERITINE Approved Use Unknown

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% OTHER https://go.drugbank.com/drugs/DB00913			ANILERIDINE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
450 mg multiple, oral (total daily dose\|max) Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319	unhealthy, 41 n = 1 Health Status: unhealthy Condition: Pain Age Group: 41 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319	Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319

AEs

AE	Significance	Dose	Population
Delirium	Disc. AE	450 mg multiple, oral (total daily dose\|max) Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319	unhealthy, 41 n = 1 Health Status: unhealthy Condition: Pain Age Group: 41 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:61203	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:61203
ZINC	ZINC000000608179	http://zinc15.docking.org/substances/ZINC000000608179

PubMed

Title	Date	PubMed
Contact dermatitis to anileridine.	1980 Dec	6894270
Qualitative differences in effects of opioids in man: preliminary evidence for multiple mechanisms of analgesic action.	1986 May	3755241
Electronic-topological study of the structure-activity relationships in a series of piperidine morphinomimetics.	2002 Aug	12171562

Patents

Sample Use Guides

In Vivo Use Guide

Aniledrine is administred either orally (in form of hydrochloride salt)

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

ANILERIDINE

Official Name

English

ANILERIDINE [HSDB]

Common Name

English

ANILERIDINE [USP IMPURITY]

Common Name

English

ADOPOL

Common Name

English

anileridine [INN]

Common Name

English

4-PIPERIDINECARBOXYLIC ACID, 1-(2-(4-AMINOPHENYL)ETHYL)-4-PHENYL-, ETHYL ESTER

Common Name

English

APIDOL

Common Name

English

ALIDINE

Common Name

English

1-P-AMINOPHENETHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER

Systematic Name

English

ANILERIDINE [MART.]

Common Name

English

NIPECOTAN

Common Name

English

ANILERIDINE [MI]

Common Name

English

Anileridine [WHO-DD]

Common Name

English

ETHYL 1-(P-AMINOPHENETHYL)-4-PHENYLISONIPECOTATE

Common Name

English

LERITIN

Common Name

English

IDS-NA-012

Code

English

Classification Tree Code System Code

DEA NO.

9020